MarketCap
Facebook
X
TelegramAnnual report 2023
added 04-16-2024
Advaxis Operating Income 2011-2025 | ADXS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Advaxis
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.3 M | -37.5 M | -18.8 M | -26.4 M | -18 M | -70.4 M | -98.4 M | -76.5 M | -48.7 M | -19.5 M | -14.7 M | -12.3 M | -13 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.3 M | -98.4 M | -37.7 M |
Quarterly Operating Income Advaxis
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.13 M | -8.49 M | -11.9 M | -4.16 M | -10.1 M | -7.85 M | -9.85 M | -3.96 M | - | -4.13 M | -6.32 M | -7.89 M | -20 M | -5.84 M | -6.32 M | 10.3 M | -7.69 M | -10.1 M | -7.87 M | -20.5 M | -48.3 M | -14.2 M | -13.6 M | -17.2 M | -70.6 M | -32.7 M | -20.7 M | -20 M | -52.1 M | -16.6 M | -15.6 M | -6.78 M | -34.2 M | -13.6 M | -13.8 M | -5.96 M | -14.6 M | -6 M | -2.6 M | -2.18 M | -10.7 M | -3.05 M | -5.48 M | -3.24 M | -10.1 M | -3.58 M | -3.23 M | -2.97 M | -9.97 M | -3.6 M | -3.41 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.3 M | -70.6 M | -12.6 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
9.14 B | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-78.1 M | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-142 M | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
BioVie
BIVI
|
-18.1 M | $ 1.54 | -2.53 % | $ 2.28 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Biogen
BIIB
|
7.04 B | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 0.29 | -5.01 % | $ 631 M |  Israel |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Benitec Biopharma
BNTC
|
-9.83 M | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 95.9 | 0.17 % | $ 27.2 B |  Germany |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Enochian Biosciences
ENOB
|
-189 M | - | - | $ 40.5 M | USA |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cerus Corporation
CERS
|
-14.2 M | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.15 | -0.44 % | $ 1.47 B | Britain |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Cellectar Biosciences
CLRB
|
-39 M | $ 3.81 | -5.35 % | $ 46.6 M | USA |
 |
Abeona Therapeutics
ABEO
|
-47.1 M | $ 5.5 | 0.46 % | $ 118 M | USA |
 |
ADiTx Therapeutics
ADTX
|
-27.9 M | $ 2.36 | -7.29 % | $ 31.1 K | USA |
 |
BioXcel Therapeutics
BTAI
|
-67.2 M | $ 2.1 | -4.34 % | $ 5.32 M | USA |
 |
Coherus BioSciences
CHRS
|
-203 M | $ 1.42 | 6.77 % | $ 134 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-24.8 M | $ 3.22 | -2.72 % | $ 908 M | Israel |
 |
Celldex Therapeutics
CLDX
|
-195 M | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Baudax Bio
BXRX
|
-56.8 M | - | 0.59 % | $ 63 K | USA |